To investigate our hypothesis that curcumin treatment could therapeutically benefit MDS patients with lower expression of GFI1 or those expressing GFI-36N, we used NUP98-HOXD13 transgenic (tg) mice as a model for MDS. This evidence concerns the gene HOXD13 and myelodysplastic syndrome.